JamesAKnostMD

PubMed

• 37 citations
  MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Can...
  Aparna Raj Parikh, Fa-Chyi Lee, Linda Yau, Han Koh, James A. Knost, Edith P. Mitchell, Ivan Bosanac, Nicholas Choong, Frank A. Scappaticci, Christoph Mancao, Heinz-Jos...> ;Clinical Cancer Research. 2019 May 15
• 5 citations
  Clinical Germline Diagnostic Exome Sequencing for Hereditary Cancer: Findings Within Novel Candidate Genes Are Prevalent
  Zöe Powis, Carin R. Espenschied, Holly LaDuca, Kelly D. Farwell Hagman, Tripti Paudyal, Shuwei Li, Hiroto Inaba, Ann Mauer, Katherine L. Nathanson, James Knost, Elizab...> ;Cancer Genetics. 2018 Aug 1
• 4 citations
  University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL
  Natalie Galanina, Sonali M. Smith, Chuanhong Liao, Adam M. Petrich, Bernadette Libao, Ronald B. Gartenhaus, Jason R. Westin, Kenneth S. Cohen, James A. Knost, Walter M...> ;British Journal of Haematology. 2018 Apr 1
• 18 citations
  The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases.
  Leora Witkowski, Nancy Donini, Rebecca Byler-Dann, James A. Knost, Steffen Albrecht, Andrew Berchuck, W. Glenn McCluggage, Martin Hasselblatt, William D. Foulkes> ;Familial Cancer. 2017 Jul 1
• 108 citations
  Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic...
  Alexa B. Schrock, Shuyu D. Li, Garrett M. Frampton, James Suh, Eduardo Braun, Ranee Mehra, Steven C. Buck, Jose A. Bufill, Nir Peled, Nagla Abdel Karim, K. Cynthia Hsi...> ;Journal of Thoracic Oncology. 2017 Jun 1
• 34 citations
  Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
  Lauren M. Thorpe, Alexa B. Schrock, Rachel L. Erlich, Vincent A. Miller, James A. Knost, Nguyet Le‐Lindqwister, Srinivas Jujjavarapu, Siraj M. Ali, Jane Liu> ;Head & Neck. 2017 Mar 1
• 55 citations
  Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and...
  Muhammad Wasif Saif, James A. Knost, E. Gabriela Chiorean, Siva Rama Prasad Kambhampati, Danni Yu, Bronislaw Pytowski, Amy Qin, John S. Kauh, Bert H. O'Neil> ;Cancer Chemotherapy and Pharmacology. 2016 Aug 26
• 66 citations
  The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
  Leora Witkowski, Catherine Goudie, Pilar Ramos, Talia Boshari, Jean Sébastien Brunet, Anthony N. Karnezis, Michel Longy, James A. Knost, Emmanouil Saloustros, W. Glenn...> ;Gynecologic Oncology. 2016 Jun 1
• 38 citations
  Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
  Manish R. Sharma, Kristen Wroblewski, Blase N. Polite, James A. Knost, James A. Wallace, Sanjiv Modi, Bethany G. Sleckman, David A. Taber, Everett E. Vokes, Walter M. ...> ;Investigational New Drugs. 2012 Jun 1
• A fixed-sequence, open-label study to determine the activity of SCH 717454 (robatumumab) as assessed by positron emission tomography in patients with relapsed or recur...
  Lin EH, Lenz H, Saleh MN, Badarinath S, Knost JA, MacKenzie MJ, Polite BN, Kavan P, Chen EX, Leichman LP, Pathiraja K, Lu BD> ;J. Clin. Oncol.. 2011-05-20
• 64 citations
  A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia
  Halla S. Nimeiri, Amit M. Oza, Robert J. Morgan, Dezheng Huo, Laurie Elit, James A. Knost, James L. Wade, Edem Agamah, Everett E. Vokes, Gini F. Fleming> ;Gynecologic Oncology. 2010 Apr 1
• 35 citations
  Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.
  Sai Murali Krishna Pulukuri, Bharathi Gorantla, James A. Knost, Jasti S. Rao> ;Oncogene. 2009 Aug 6
• Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and Calif...
  Nimeiri HS, Oza AM, Morgan RJ, Huo D, Elit L, Knost J, Wade Iii JL, Agamah E, Vokes EE, Fleming GF> ;J. Clin. Oncol.. 2008-05-20
• 18 citations
  A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
  Amy C. Peterson, Helena Harlin, Theodore Karrison, Nicholas J. Vogelzang, James A. Knost, John W. Kugler, Eric P. Lester, Everett E. Vokes, Thomas F. Gajewski, Walter ...> ;Investigational New Drugs. 2006 Feb 28
• Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North...
  Jatoi, A., Murphy, B. R., Foster, N. R., Nikcevich, D. A., Alberts, S. R., Knost, J. A., Fitch, T. R., Rowland, K. M.> ;Ann Oncol. 2006 Jan
• A randomized phase II trial of Interleukin-2 in combination with four different doses of bryostatin in patients with renal cell carcinoma.
  Peterson AC, Harlin H, Karrison T, Knost JA, Kugler JW, Vogelzang NJ, Vokes EE, Gajewski TF, Stadler WM> ;J. Clin. Oncol.. 2004-07-15
• 73 citations
  Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking
  Richard D. Hurt, James E. Krook, Ivana T. Croghan, Charles L. Loprinzi, Jeff A. Sloan, Paul J. Novotny, Carl G. Kardinal, James A. Knost, Maria Tria Tirona, Ferdinand ...> ;Journal of Clinical Oncology. 2003 Mar 1
• 11 citations
  Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisp...
  Harry J. Long, Sandra Rayson, Karl C. Podratz, Samir Abu-Ghazaleh, Vera J. Suman, Lynn C. Hartmann, Ralph Levitt, Suresh G. Nair Md, Alan K. Hatfield, James A. Knost> ;American Journal of Clinical Oncology. 2002 Dec 1
• 10 citations
  Comparison of lymphoid neoplasm classification. A blinded study between a community and an academic setting.
  James D. Siebert, Leigh Anne C. Harvey, Paul A. S. Fishkin, James A. Knost, Aamir Ehsan, Bassam N. Smir, Fiona E. Craig> ;American Journal of Clinical Pathology. 2001 May 1
• 38 citations
  Utility of Flow Cytometry Immunophenotyping for the Diagnosis and Classification of Lymphoma in Community Hospital Clinical Needle Aspiration/Biopsies
  James D. Siebert, Lori M. Weeks, Larry W. List, John W. Kugler, James A. Knost, Paul A. S. Fishkin, Mark H. Goergen> ;Archives of Pathology & Laboratory Medicine. 2000 Dec 1
• 12 citations
  A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
  Henry C. Pitot, James A. Knost, Michelle R. Mahoney, John Kugler, James E. Krook, Alan K. Hatfield, Daniel J. Sargent, Richard M. Goldberg> ;Cancer. 2000 Oct 15
• 25 citations
  A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer.
  John J Weitz, Robert F. Marschke, Jeff A. Sloan, Joseph P. Grill, James R. Jett, James A. Knost, Alan K. Hatfield, David W Zenk, Walter W. Bate, Paul L. Schaefer> ;Lung Cancer. 2000 May 1
• 271 citations
  Evaluation of Soy Phytoestrogens for the Treatment of Hot Flashes in Breast Cancer Survivors: A North Central Cancer Treatment Group Trial
  Susan K. Quella, Charles L. Loprinzi, Debra L. Barton, James A. Knost, Jeff A. Sloan, Beth I. LaVasseur, Debra K. Swan, Kenneth R. Krupp, Kathy D. Miller, Paul J. Novotny> ;Journal of Clinical Oncology. 2000 Mar 1
• 10 citations
  Utility of flow cytometry in subtyping composite and sequential lymphoma.
  James D. Siebert, Debra A. Mulvaney, Allen M. Vukov, James A. Knost, David E. King, Fiona E. Craig> ;Journal of Clinical Laboratory Analysis. 1999 Jan 1
• 29 citations
  Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer
  Sridhar Mani, John W. Kugler, James A. Knost, David F. Sciortino, Joseph Gibbons, Juan C. Garcia, Rafat Ansari, Richard L. Schilsky, Everett E. Vokes> ;Investigational New Drugs. 1998 Jan 1
• Join now to see all